Valo Health CEO David Berry to Participate in 2022 BIO CEO & Investor Conference

BOSTON, MA (Feb­ru­ary 8, 2022) — Valo Health, LLC (“Valo”), the tech­nol­o­gy com­pa­ny using human-cen­tric data and arti­fi­cial intel­li­gence (AI) pow­ered com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process, today announced that its CEO and Founder, David Berry, M.D. PhD, will par­tic­i­pate in a pan­el dis­cus­sion at the BIO CEO & Investor Con­fer­ence being held in New York, NY and vir­tu­al­ly, on Feb­ru­ary 14, 2022 at 10:00 AM regard­ing Ven­ture Investor Trends in Biotech.”

For more infor­ma­tion about the con­fer­ence, please vis­it the con­fer­ence web­site. A video web­cast of the pre­sen­ta­tion will be avail­able for view­ing on-demand for those reg­is­tered for the event.

About Valo Health, Inc.

Valo Health, LLC (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence (“AI”) com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to full inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The company’s Opal Com­pu­ta­tion­al Plat­form™ con­sists of an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and in Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.


Investors: Graeme Bell, Chief Finan­cial Officer


Media: Jen­nifer Han­ley, VP Cor­po­rate Communications